No biomarker	Soft Tissue Sarcoma	No biomarker	Soft Tissue Sarcoma	L-ANN Sensitive: B - Late Trials L-ANN Sensitive : B	L-ANN Sensitive: B - Late Trials L-ANN Sensitive : B
No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	L-ANN Sensitive: B - Late Trials L-ANN Sensitive : B	L-ANN Sensitive: B - Late Trials L-ANN Sensitive : B
TOP2A overexpression	Adrenal Cortex Carcinoma	TOP2A overexpression	Adrenal Cortex Carcinoma	rubitecan Sensitive: D – Preclinical rubitecan Sensitive : D	rubitecan Sensitive: D – Preclinical rubitecan Sensitive : D
TOP2A overexpression	Adrenal Cortex Carcinoma	TOP2A overexpression	Adrenal Cortex Carcinoma	pirarubicin Sensitive: D – Preclinical pirarubicin Sensitive : D	pirarubicin Sensitive: D – Preclinical pirarubicin Sensitive : D
ATR mutation	Colorectal Cancer	ATR mutation	Colorectal Cancer	M6620 + SNB-101 Sensitive: D – Preclinical M6620 + SNB-101 Sensitive : D	M6620 + SNB-101 Sensitive: D – Preclinical M6620 + SNB-101 Sensitive : D
ATR mutation	Colorectal Cancer	ATR mutation	Colorectal Cancer	SNB-101 Sensitive: D – Preclinical SNB-101 Sensitive : D	SNB-101 Sensitive: D – Preclinical SNB-101 Sensitive : D

DNA topoisomerase inhibitor

Associations(6)